This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaufman, E. N. Articles by Jain, R. K. Search for Related Content PubMed PubMed Citation Articles by Kaufman, E. N. Articles by Jain, R. K.

Effect of Bivalent Interaction upon Apparent Antibody Affinity: Experimental Confirmation of Theory Using Fluorescence Photobleaching and Implications for Antibody Binding Assays¹

Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213-3890 [E. N. K.], and Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 [R. K. J.]

The affinity of a monoclonal antibody for its tumor-associated antigen is one of several parameters governing in vivo monoclonal antibody distribution. However, there is a lack of apparent correlation between the affinity of a bivalent monoclonal antibody measured using equilibrium binding experiments and its in vivo delivery. Furthermore, differences in the reported affinity for identical antibody/antigen pairs are quite common in the literature. In this paper, both of these discrepancies are addressed in terms of variation in avidity due to bivalent interaction. The enhancement of avidity afforded by bivalent attachment is addressed theoretically by extending the model of Crothers and Metzger (Immunochemistry, 9: 341–357, 1972). Theoretical assessment of Line-weaver-Burk, Scatchard, Steward-Petty, Langmuir, fluorescence recovery after photobleaching, and Sips models demonstrates quantitatively that the measured affinity using equilibrium binding experiments may vary over four orders of magnitude with similar variation in experimental cellular antigen density. Further, the measured affinity is a function of the experimental protocol. Predictions of avidity enhancement were confirmed experimentally using fluorescence recovery after photobleaching. These experiments measured the equilibrium binding constant and concentration of binding sites for an immunoglobulin G monoclonal antibody and its F(ab) fragment directed against the rabbit VX2 carcinoma cell line. Bivalent binding data agree quantitatively with those predicted by the bivalent model with no adjustable parameters. It is concluded that bivalent equilibrium binding constants are useful only in antibody screening, where experimental conditions are identical for all series. They must be used with caution in predicting in vivo antibody distribution, and it is recommended that the intrinsic, monovalent affinity be measured in tandem with any bivalent antibody study as a standard reference.

¹ This work was supported by National Science Foundation Grant CBT-88-16062 and National Cancer Institute Grants CA36902 and CA49792.

² To whom requests for reprints should be addressed.

Received 3/11/92. Accepted 5/14/92.

This article has been cited by other articles:

				B. C. Satterfield, J. A.A. West, and M. R. Caplan Tentacle probes: eliminating false positives without sacrificing sensitivity Nucleic Acids Res., May 21, 2007; (2007) gkm113v1. [Abstract] [Full Text] [PDF]

				E. L. Hill, T. Gallopin, I. Ferezou, B. Cauli, J. Rossier, P. Schweitzer, and B. Lambolez Functional CB1 Receptors Are Broadly Expressed in Neocortical GABAergic and Glutamatergic Neurons J Neurophysiol, April 1, 2007; 97(4): 2580 - 2589. [Abstract] [Full Text] [PDF]

				X. H. Yang, O. V. Kovalenko, T. V. Kolesnikova, M. M. Andzelm, E. Rubinstein, J. L. Strominger, and M. E. Hemler Contrasting Effects of EWI Proteins, Integrins, and Protein Palmitoylation on Cell Surface CD9 Organization J. Biol. Chem., May 5, 2006; 281(18): 12976 - 12985. [Abstract] [Full Text] [PDF]

				S Cucnik, T Kveder, I Krizaj, B Rozman, and B Bozic High avidity anti-{beta}2-glycoprotein I antibodies in patients with antiphospholipid syndrome Ann Rheum Dis, November 1, 2004; 63(11): 1478 - 1482. [Abstract] [Full Text] [PDF]

				A. Goel, D. Colcher, J. Baranowska-Kortylewicz, S. Augustine, B. J. M. Booth, G. Pavlinkova, and S. K. Batra Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application Cancer Res., December 1, 2000; 60(24): 6964 - 6971. [Abstract] [Full Text]

				L. S. Zuckier, E. Z. Berkowitz, R. J. Sattenberg, Q. H. Zhao, H. F. Deng, and M. D. Scharff Influence of Affinity and Antigen Density on Antibody Localization in a Modifiable Tumor Targeting Model Cancer Res., December 1, 2000; 60(24): 7008 - 7013. [Abstract] [Full Text]

				U. B. Nielsen, G. P. Adams, L. M. Weiner, and J. D. Marks Targeting of Bivalent Anti-ErbB2 Diabody Antibody Fragments to Tumor Cells Is Independent of the Intrinsic Antibody Affinity Cancer Res., November 1, 2000; 60(22): 6434 - 6440. [Abstract] [Full Text]

				D. A. Berk, F. Yuan, M. Leunig, and R. K. Jain Direct in vivo measurement of targeted binding in a human tumor xenograft PNAS, March 4, 1997; 94(5): 1785 - 1790. [Abstract] [Full Text] [PDF]